- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Over 2,000 real rulings — analysed for what they mean to your team. Published every day.
Showing 1914 cases
Anonymous alleged pharma-funded conference hospitality (hotel/food/cultural programme). Panel found Janssen-Cilag’s £2,000 educational grant and speaker support was acceptable; no evidence it funded…
Anonymous complaint said a Qvar ad in Pulse used partially clothed people and undermined the serious nature of medicines. Panel found the…
DTB criticism triggered a PMCPA case on Pfizer’s Exubera materials claiming “maintains long-term glycaemic control”. Panel found the unqualified long-term claim misleading…
Novartis’ Femara leavepiece implied extra benefit in node-positive/chemo subgroups vs overall trial effect, and a press release claimed licensing across the “entire”…
Actonel materials and a sponsored symposium slide were ruled misleading/disparaging about Bonviva (ibandronate). A patient telephone survey was not disguised promotion. Breaches:…
Grünenthal voluntarily admitted breaching an undertaking when Pulse re-ran an old Versatis ad previously ruled in breach. Panel found Clause 22 breach;…
A pharmacist said a Fluad email implied JCVI policy changed for all 65+ and overstated cost-effectiveness. Panel found draft JCVI source was…
PMCPA Director’s case on Takeda clinical trial disclosure for Rienso. The matter was found to be outwith the scope of the ABPI…
Complaint about promotion of Nexplanon. PMCPA concluded no breach and that the matter was outwith the scope of the ABPI Code (2016).…
Observer article criticised Sanofi-Aventis-funded trip for cancer charity leaders/policymakers to Budapest (EACR) and Paris. PMCPA found the programme educational, hospitality proportionate and…
A doctor alleged a Vistabel (POM) ad appeared in a journal accessible to non-HCPs. The Panel held the publication was aimed at…
A ‘Dear Doctor’ letter said Dovobet could replace Dovonex for “the majority” of patients, without clearly explaining key differences (incl. potent steroid…
Lilly challenged Levitra ad/leavepiece claims including “Works first time in 9 out of 10 men”, “wine and dine”, and “many men prefer”.…
Invokana virtual booth email/microsite breached the Code for incomplete prescribing info, misleading headline claims implying significance, missing Vokanamet generic name, and failure…
GSK’s UK cervical cancer disease awareness field team was initially cleared, but on appeal the cumulative arrangements were ruled to promote an…
Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.